Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS-CoV-2 Omicron (BA.5) challenge strain
- Development stage
- Unknown
- Lead developer
- hVIVO
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intranasal
01
Overview
SARS-CoV-2 Omicron (BA.5) challenge strain is a live-virus preparation developed by Hvivo for use in human challenge clinical trials. It is specifically designed to induce a controlled SARS-CoV-2 infection in healthy volunteers to evaluate the pathogenicity of the Omicron BA.5 variant and to establish a standardized model for testing the efficacy of vaccines and therapeutic interventions. The virus is typically administered intranasally to mimic natural infection. Unlike a vaccine or therapeutic, this is a "challenge agent" used to intentionally infect healthy volunteers in a controlled environment to study the virus's pathogenicity, establish the minimum infectious dose, and provide a model for testing the efficacy of future vaccines and antivirals.
- Other names
- SARS-CoV-2 Omicron BA.5 challenge virusSARS-CoV2 Omicron BA.5 challenge virusSARS-CoV 2 Omicron BA.5 challenge virusSARS-CoV-2 Omicron BA.5 challenge agentSARS-CoV2 Omicron BA.5 challenge agentSARS-CoV 2 Omicron BA.5 challenge agent
02
Targets
ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on SARS-CoV-2 Omicron (BA.5) challenge strain.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS-CoV-2 Omicron (BA.5) challenge strain.